Form 8-K - Current report:
SEC Accession No. 0001628280-22-019570
Filing Date
2022-07-27
Accepted
2022-07-27 16:05:48
Documents
14
Period of Report
2022-07-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K gthx-20220727.htm   iXBRL 8-K 43580
2 EX-99.1 pressrelease-bodadditionxn.htm EX-99.1 11989
6 g1logoa.jpg GRAPHIC 22056
  Complete submission text file 0001628280-22-019570.txt   232910

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gthx-20220727.xsd EX-101.SCH 1920
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gthx-20220727_lab.xml EX-101.LAB 24849
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gthx-20220727_pre.xml EX-101.PRE 13058
8 EXTRACTED XBRL INSTANCE DOCUMENT gthx-20220727_htm.xml XML 11823
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

EIN.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 221111053
SIC: 2834 Pharmaceutical Preparations